RHA Dynamic Volume filler can now be injected in the cheeks and midface.

The U.S. Food and Drug Administration (FDA) has approved RHA Dynamic Volume, from Teoxane and Revance, for cheek augmentation and correction of age related midface contour deficiencies in adults aged 22 and older. 

The product, formerly known as RHA 4 Mepi, will launch under its updated name in early 2026 and introduces a new option for midface volumization that emphasizes natural movement and long lasting results.

"We are incredibly proud of the approval for midface with RHA® Dynamic Volume. This news marks the second major advancement from the Teoxane RHA® Collection in the past few months, following the evolution of the Teoxane RHA® Collection through the introduction of the local anesthetic Mepivacaine in late August. The new midface indication enables us to meet more patient needs than ever before," shares Nadeem Moiz, CEO of Revance. "Revance remains committed to innovating and providing diverse treatment options to address a variety of patient concerns."

RHA Dynamic Volume is a hyaluronic acid dermal filler engineered to support dynamic contour enhancement, offering high structural integrity and stretch while preserving natural facial movement. The product is formulated using Preserved Network Technology (PNT), a gentle and heatless crosslinking process designed to maintain the natural structure of hyaluronic acid.

The approval is supported by a 52 week Phase III clinical trial comparing RHA Dynamic Volume to Juvéderm Voluma XC in patients with moderate to severe midface volume loss. In the study:

• RHA Dynamic Volume demonstrated comparable effectiveness to Voluma.
• Patients required fewer treatment sessions and fewer touch ups to achieve similar outcomes.
• More than 94 percent of participants reported natural-looking and natural-feeling results at rest and in motion for up to one year.
• Patients reported no perception of restricted facial movement.
• Clinical results reported no late onset or serious treatment related adverse events, and no instances of granuloma or delayed inflammatory response.

The new on-label indication allows Revance, Teoxane and CME-accredited institutions to officially offer training for these FDA-approved treatment areas. 

New approved uses make the RHA filler a more versatile tool in your injector's toolkit.

Learn more about the Teoxane RHA Collection of resilient hyaluronic acid (HA) fillers, and read important safety information at rha.revanceaesthetics.com.